Not FDA-approved
Brain & sleep
Semax
Evidence
Regional approval, limited trials
Class
Synthetic heptapeptide related to ACTH
KEY TAKEAWAY
Semax is a short synthetic peptide developed in Russia, where it is used as a nasal medicine for stroke recovery and some cognitive conditions. It is not approved by the FDA and high-quality Western trials are lacking.
Written by the Veylo editorial team · Updated
November 2026
What it is
A synthetic peptide modeled on part of the ACTH hormone
Studied for
Stroke recovery, cognitive function and neuroprotection
Key fact
Approved in Russia; little evidence from trials outside that region
Route
Nasal spray
Evidence strength
Regional approval, limited trials
Semax is a seven-amino-acid peptide derived from a fragment of adrenocorticotropic hormone, altered to resist breakdown.
Animal and cell studies suggest it raises levels of brain-derived neurotrophic factor and affects neurotransmitter systems. How strongly this applies in people is not established.
Semax is used as a drug in Russia and some neighboring countries. It is not approved by the FDA.
In Russia it is used after ischemic stroke and for certain cognitive and optic nerve conditions. Other uses are off-label or experimental.
Reported effects are generally mild and include nasal irritation. Safety data from large, independent trials are limited.
Primary literature for this entry is being compiled.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.